|
WO2021077117A1
|
|
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
WO2021071962A1
|
|
Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
|
|
WO2021062281A2
|
|
Multi-targeting effector cells and use thereof
|
|
WO2021011919A1
|
|
Immune effector cell engineering and use thereof
|
|
WO2020210398A1
|
|
CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS
|
|
WO2020117526A1
|
|
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
|
|
BR112020019205A2
|
|
GENETICALLY MODIFIED IMMUNE CELLS AND USE OF THE SAME
|
|
KR20200102454A
|
|
Improved immune effector cells and uses thereof
|
|
US2021015859A1
|
|
IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
|
|
AU2018348142A1
|
|
Cellular reprogramming using temporal and transient plasmid vector expression system
|
|
US2020179451A1
|
|
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
EP3638775A1
|
|
Compositions and methods for inducing myeloid suppressive cells and use thereof
|
|
WO2018106595A1
|
|
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
EP3405568A1
|
|
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
CN108473959A
|
|
For carrying out the composition and method of immunocyte adjusting in adoptive immunotherapy
|
|
WO2017079673A1
|
|
Genomic engineering of pluripotent cells
|
|
AU2016338680A1
|
|
Platform for the induction and maintenance of ground state pluripotency
|
|
AU2016348342A1
|
|
Methods and compositions for inducing hematopoietic cell differentiation
|
|
US2019119635A1
|
|
Modulation of t lymphocytes
|
|
CN107429230A
|
|
Method and composition for induction of hematopoiesis cell differentiation
|
